Analyzing IDEXX Laboratories (IDXX) & Response Genetics (RGDXQ)

IDEXX Laboratories (NASDAQ:IDXX) and Response Genetics (OTCMKTS:RGDXQ) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their profitability, institutional ownership, dividends, risk, analyst recommendations, earnings and valuation.

Institutional & Insider Ownership

91.1% of IDEXX Laboratories shares are held by institutional investors. 2.6% of IDEXX Laboratories shares are held by company insiders. Comparatively, 4.9% of Response Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Valuation and Earnings

This table compares IDEXX Laboratories and Response Genetics’ revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
IDEXX Laboratories $1.97 billion 9.01 $263.14 million $3.28 62.47
Response Genetics N/A N/A N/A N/A N/A

IDEXX Laboratories has higher revenue and earnings than Response Genetics.

Volatility and Risk

IDEXX Laboratories has a beta of 0.82, suggesting that its share price is 18% less volatile than the S&P 500. Comparatively, Response Genetics has a beta of -0.61, suggesting that its share price is 161% less volatile than the S&P 500.

Profitability

This table compares IDEXX Laboratories and Response Genetics’ net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
IDEXX Laboratories 15.19% -994.76% 23.09%
Response Genetics N/A N/A N/A

Analyst Recommendations

This is a summary of current ratings and price targets for IDEXX Laboratories and Response Genetics, as provided by MarketBeat.com.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
IDEXX Laboratories 1 0 5 0 2.67
Response Genetics 0 0 0 0 N/A

IDEXX Laboratories currently has a consensus price target of $241.00, indicating a potential upside of 17.61%. Given IDEXX Laboratories’ higher possible upside, equities analysts clearly believe IDEXX Laboratories is more favorable than Response Genetics.

Summary

IDEXX Laboratories beats Response Genetics on 7 of the 9 factors compared between the two stocks.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc., together with its subsidiaries, develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets worldwide. It operates through Companion Animal Group; Water Quality Products; Livestock, Poultry and Dairy; and Other segments. The company provides point-of-care veterinary diagnostic products, including instruments, consumables, and rapid assay test kits; veterinary reference laboratory diagnostic and consulting services; practice management and diagnostic imaging systems and services for veterinarians; and biological materials testing, and laboratory animal diagnostic instruments and services for biomedical research community. It also offers diagnostic and health-monitoring products for livestock, poultry, and dairy markets; products that test water for various microbiological contaminants; and point-of-care electrolytes and blood gas analyzers that are used in the human point-of-care medical diagnostics market. The company markets its products through marketing, customer service, sales, and technical service groups, as well as through independent distributors and other resellers. IDEXX Laboratories, Inc. was founded in 1983 and is headquartered in Westbrook, Maine.

Response Genetics Company Profile

Response Genetics, Inc., a life sciences company, researches, develops, markets, and sells pharmacogenomic tests for use in the treatment of cancer in the United States, Europe, and internationally. The company offers tests for measuring predictive factors for therapy response in tumor tissue samples. It provides testing services for non-small cell lung cancer, colorectal cancer, gastric and gastroesophageal cancer, melanoma and thyroid cancer, breast cancer, and glioma through its ResponseDX: Lung, ResponseDX: Colon, ResponseDX: Gastric, ResponseDX: Melanoma, ResponseDX: Thyroid, ResponseDX: Breast, ResponseDX: Glioma, and ResponseDX: Tissue of Origin test suites. The company also develops tests for other tumor types; and provides technical component and professional component testing services. It serves community based oncologists, pathologists, physician offices, hospitals, and pharmaceutical companies through its sales force. The company was formerly known as Bio Type, Inc. and changed its name to Response Genetics, Inc. in August 2000. Response Genetics, Inc. was founded in 1999 and is headquartered in Los Angeles, California.

Receive News & Ratings for IDEXX Laboratories Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply